Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia.
Curr HIV/AIDS Rep. 2012 Mar;9(1):5-15. doi: 10.1007/s11904-011-0108-2.
Combination antiretroviral therapy (cART) has led to a reduction in morbidity and mortality in HIV-infected patients but therapy is lifelong and there is no cure for HIV. The major barriers to cure include HIV latency, which has been identified in different T-cell subsets, as well as persistence of HIV in anatomical reservoirs. We review recent developments in our understanding of the major reservoirs of HIV in patients on cART as well as how latency is established and maintained in T cells. Finally, we review the scientific rationale of and clinical experience with pharmacotherapeutic strategies aimed at eliminating latently infected cells.
联合抗逆转录病毒疗法（cART）降低了感染 HIV 患者的发病率和死亡率，但该疗法需要终身进行，且 HIV 目前无法治愈。治愈的主要障碍包括 HIV 潜伏期，它存在于不同的 T 细胞亚群中，以及 HIV 在解剖学储库中的持续存在。我们回顾了 cART 患者中 HIV 主要储库的最新研究进展，以及潜伏期在 T 细胞中是如何建立和维持的。最后，我们回顾了旨在消除潜伏感染细胞的药物治疗策略的科学依据和临床经验。
